Replies to post #6810 on Halozyme Therapeutics Inc (HALO)

[biotechinvestor1]

We know from the SA article that Faspro already has a coformulation patent and others are in the works. On every presentation, Helen has also reiterated a 40% CAGR in royalties for every year between now and 2027. This is all based on existing programs and not dependent on new partnerships.

However, if this not clear to you, then perhaps there are others who don’t understand it either and she should explain it more clearly. The Seeking Alpha article on this topic is helpful.